Naseem Chini heads the overall operation of the Clinical Analysis Laboratory. The laboratory is a fully GLP-compliant clinical testing facility providing high-quality GLP and non-GLP clinical lab services in clinical chemistry, hematology, coagulation, urinalysis, and specialized biomarkers.

Prior to joining SRI, Chini worked in clinical settings at Cedars-Sinai Medical Center and Stanford University Medical Center, as well as in the biotech/pharmaceutical industry at Roche Biosciences and Cholestech Corporation. She is currently involved in the establishment and GLP validation of the FDA biomarkers of toxicity program developed by the Preclinical Safety Testing consortium—a group of 15 large pharmaceutical companies, the Critical Path institute, the U.S. Food and Drug Administration, and SRI.

Chini received a bachelors of science degree from California State University, Northridge. She holds a Clinical Laboratory Scientist license from State of California Department of Public Health and a National Medical Technology license from American Society for Clinical Pathology.